1988 DOI: 10.1016/0014-5793(88)80509-x PMID: 3169264 Read on PubMed Advances in Experimental Medicine and Biology Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation Miller DM, DeSilva D, Pickart L 1990 DOI: 10.1007/978-1-4684-5730-8_11 PMID: 2244543 Read on PubMed Cosmetics GHK and DNA: Resetting the Human Genome to Health Pickart L, Vasquez-Soltero JM, Margolina A 2014 DOI: 10.1155/2014/151479 PMID: 25210707 Read on PubMed FASEB Journal Tripeptide-copper complex GHK-Cu(2+) transiently activates the inflammatory response in Jurkat T-cells and B-cell lymphoma cells Gruchlik A, Jurzak M, Chodurek E, Dzierewicz Z 2010 DOI: 10.1096/fasebj.24.1_supplement.lb87 PMID: 20639517 Read on PubMed Experimental Dermatology Effect of the tripeptide-copper complex L-alanyl-L-histidyl-L-lysine-Cu2+ on hair growth in C57BL/6 mice Pyo HK, Yoo HG, Won CH, et al
The trial did not resume enrollment Preclinical cardiac evidence: Animal models of myocardial infarction demonstrated RGN-352 reduced scar volume, improved cardiac function, and increased survival, forming the basis for the clinical program (PMID: 25015963) RGN-259 (Thymosin Beta-4 Ophthalmic Solution for Dry Eye): ARISE-1 and ARISE-2 Phase 3 trials: Evaluated Thymosin Beta-4 eye drops for dry eye disease with mixed results some endpoints showed improvement in signs of dry eye, but the pre-specified co-primary endpoints were not met, though some secondary endpoints showed statistically significant improvements in certain signs of dry eye (PMID: 23050815) These ophthalmic trials represent the most advanced clinical testing of any Thymosin Beta-4 formulation Independent Pilot Study (China, 2016): A small pilot study randomized 10 STEMI (heart attack) patients into two groups: 5 receiving Thymosin Beta-4-pretreated endothelial progenitor cells (EPCs) and 5 receiving untreated EPCs After 6 months, the Thymosin Beta-4-pretreated group showed trends toward improved cardiac function markers including ejection fraction and exercise capacity, though the very small sample size (n=5 per group) means these results should be considered hypothesis-generating only, not evidence of efficacy (PMID: 27288307) No severe complications were reported in either group during follow-up Important: This study used Thymosin Beta-4 as a cell pretreatment agent ex vivo (EPCs exposed to TB4 before transplantation), not as a directly administered drug
Over time, BPC 157 may help ease that, resulting in a less painful and easier recovery
This is not a race
